David Edward Johnson bought $1.2M of Exelixis (EXEL)
Executed Nov 25 2025, disclosed Nov 26 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Nov 26 2025), the stock returned +7.5% (delay-adjusted); from the execution session (Nov 25 2025), +9.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
David Edward Johnson (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Exelixis, Inc. (EXEL). Across 1 priced purchase filing, the average 21-session return was +9.4% from execution and +7.5% from disclosure (delay-adjusted; derived). The largest single filing was $1.2M of EXEL (27,532 sh × $43.12, as filed), executed Nov 25 2025.
Healthcare · Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat c…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→